MetaModix has filed a notice of an exempt offering of securities to raise $2,000,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, MetaModix is raising $2,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Kedar Belhe played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About MetaModix
Metamodix is dedicated to reducing the human and financial costs of Type 2 Diabetes. We have developed a drug-free, nonsurgical device therapy that promises to eliminate symptoms and reduce weight in those who suffer from Type 2 Diabetes more than 300 million patients worldwide.
To learn more about MetaModix, visit http://www.metamodix.com/
Contact:
Kedar Belhe, President and Chief Executive Officer
763-244-1248
https://www.linkedin.com/in/kedar-belhe-36461511/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.